As patients who are receiving treatments via expanded access for diseases are outside of the controlled environment of a clinical trial, their experiences may be considered to be more “real-world.” A multi-national chart review has shown that the success of treatments given through expanded access was mirrored in clinical trials, then after approval and mass market availability. To see what was considered in the review: